1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Piprot, C; Cals, L; Chaigneau, L; Demarchi, F; N'Guyen, T; Stein, U; Villanueva, C; Bréau, JL; Chouahnia, AK; Saintigny, P; Boué, F; deSaint-Hilaire, P; Guimont, I; Grossat, N; Valenza, B; Lévy, E; Médioni, J; Delbaldo, C; Grenier, J; Pouessel, D Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Venat-Bouvet, Laurence; Cany, Laurent; Catal... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 791OUpdated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. (23rd October 2018) Authors: Fizazi, K; Carmel, A; Joly, F; Delva, R; Gravis, G; Rolland, F; Priou, F; Ferrero, J-M; Houede, N; Mourey, L; Theodore, C; Krakowski, I; Berdah, J-F; Baciuchka Palmaro, M; Laguerre, B; Flechon, A; Ravaud, A; Brihoum, M; Culine, S; Le Teuff, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗